Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283374
Status:
TERMINATED
Last Update Posted:
2006-05-18
First Post:
2006-01-25
Brief Title:
Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Prospective Longitudinal Multicenter Nontreatment Exploratory Biomarker Study of Metabolic Syndrome in Subjects Undergoing Laparoscopic Roux-En-Y Gastric Bypass Bariatric Syndrome
Status:
TERMINATED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving Patients with this syndrome are at increased risk for cardiovascular disease and at increased risk of mortality from cardiovascular disease
Metabolic syndrome is strongly associated with obesity and more specifically with abdominal obesity Abdominal obesity comprises two main components visceral VAT and subcutaneous SAT adipose tissue depots with VAT reported as more metabolically active than SAT and thought to play a major role in the metabolic disturbances associated with obesity and metabolic syndrome
Non-alcoholic fatty liver disease NAFLD is fast becoming the most common liver disease and is associated with obesity insulin resistance and metabolic syndrome
Bariatric surgery has yielded dramatic results including longitudinal loss of excess body weight and either complete reversal or significant improvement of several features of metabolic syndrome NAFLD and nonalcoholic steatohepatitis NASH in obese patients
Metabolic syndrome is strongly associated with obesity and more specifically with abdominal obesity Abdominal obesity comprises two main components visceral VAT and subcutaneous SAT adipose tissue depots with VAT reported as more metabolically active than SAT and thought to play a major role in the metabolic disturbances associated with obesity and metabolic syndrome
Non-alcoholic fatty liver disease NAFLD is fast becoming the most common liver disease and is associated with obesity insulin resistance and metabolic syndrome
Bariatric surgery has yielded dramatic results including longitudinal loss of excess body weight and either complete reversal or significant improvement of several features of metabolic syndrome NAFLD and nonalcoholic steatohepatitis NASH in obese patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None